A Contract Research Organisation (CRO) may assume responsibility for regulatory submissions, study start-up, monitoring, site management, pharmacovigilance, data management and other activities that directly affect participant protection and the reliability of trial results. For this reason, knowing how to choose a CRO clinical trial partner is a central part of development planning.
Table of Contents
To choose a CRO clinical trial partner with suitable expertise, sponsors should request evidence from comparable projects, including case studies and relevant regulatory submissions and recruitment experience.
CRO selection should therefore consider scientific expertise, regulatory capability, execution capacity and the mechanisms through which the sponsor will retain visibility and control throughout the study. The right partner should provide the structure and transparency required to keep the trial aligned with its scientific objectives and regulatory obligations.
Before choosing a CRO: what does your clinical trial actually require?
Before approaching potential providers, sponsors should define the study’s clinical and operational requirements. These include:
- Investigational product;
- Therapeutic indication;
- Phase;
- Design;
- Target population;
- Geographical scope;
- Timeline;
- Regulatory pathway.
The outsourcing model must also be established. Sponsors with substantial internal capacity may require support in selected functions, such as monitoring or data management. By contrast, smaller biotechnology companies may benefit from a full-service model covering study preparation, regulatory activities and clinical execution. Alternatively, hybrid arrangements can combine internal and external capabilities, provided that responsibilities and interfaces remain clearly defined.
When preparing to choose a CRO clinical trial partner, sponsors should identify:
- The activities and deliverables to be outsourced;
- The countries, sites and participant population involved;
- The principal quality, recruitment and timeline risks;
- The systems and vendors required;
- The internal resources available for oversight;
- The budget assumptions and selection criteria.
This preliminary work allows competing proposals to be developed against a common scope and reduces the likelihood of omissions emerging during contracting or study start-up.
How to choose a CRO clinical trial partner: the 7 criteria sponsors should assess
To choose a CRO clinical trial partner effectively, sponsors should look beyond the breadth of a provider’s service portfolio and examine how its capabilities align with the specific demands of the study. The following seven criteria provide a practical basis for comparing potential partners and identifying risks that may affect trial execution:
1. Does the CRO have relevant therapeutic area and trial-phase experience?
Clinical research experience should be assessed in relation to the indication, study population, intervention and trial phase. A first-in-human study may require intensive safety oversight and pharmacokinetic coordination, while a multinational later-phase trial places greater demands on recruitment, site management and data consistency.
2. Can its service model and operational capacity match the study?
The outsourcing model should reflect the sponsor’s internal resources and the scope of the trial. The main options are:
- Full-service model: one CRO manages most or all trial functions, which can simplify coordination and reduce the number of operational interfaces;
- Functional Service Provider (FSP) model: the sponsor outsources specific activities, such as data management or pharmacovigilance, while retaining direct control over the wider study;
- Hybrid model: responsibilities are divided between the sponsor, a full-service CRO and/or specialist providers, allowing greater flexibility when internal capabilities vary across functions.
Sponsors should also examine the proposed resource plan, geographical coverage, staffing levels and reliance on subcontractors, as well as how workload and unexpected changes in scope will be managed.
3. Does the CRO understand the applicable regulatory pathway?
Regulatory capability should be assessed against the product, development stage, study design and jurisdictions involved. Familiarity with Good Clinical Practice (GCP) provides an essential foundation, but sponsors should also examine whether the CRO can interpret the requirements that apply to the specific trial, prepare the necessary documentation and coordinate submissions across regulatory authorities, ethics committees and other competent bodies.
For multinational studies, this may include experience with the EU Clinical Trials Regulation and the Clinical Trials Information System (CTIS), FDA requirements in the United States, and country-specific submission, safety-reporting and data-protection obligations. When preparing to choose a CRO clinical trial partner, sponsors should therefore clarify how authority interactions and local requirements will be managed across the countries concerned.
4. Are its quality management and monitoring systems robust?
The CRO should operate through a structured Quality Management System (QMS) covering procedures, training, audits, deviation management and corrective and preventive actions. Its monitoring approach should also reflect the specific risks of the study.
Sponsors should ask how critical data and processes will be identified and how recurring or systemic issues will be investigated. Timely access to monitoring results is essential, since effective oversight depends on the sponsor’s ability to assess emerging risks and verify whether corrective measures have produced the intended result.
5. Can the CRO deliver realistic site and participant recruitment strategies?
A broad investigator network does not necessarily provide access to the population required by the protocol. Site feasibility should consider:
- Previous performance;
- Competing studies;
- Eligibility criteria;
- Staff capacity;
- The practical demands that study participation will place on participants.
Recruitment projections should be supported by explicit assumptions and relevant data, including expected screening rates, screen-failure rates, activation timelines and predefined responses to underperformance at site, country or strategy level.
6. Are its technology and data capabilities fit for purpose?
The CRO’s systems should support reliable data handling, traceability and appropriate access to study information. Depending on the study design, this may involve platforms such as EDC, CTMS, eTMF, RTSM, ePRO or eCOA, together with suitable integrations.
When sponsors choose a CRO clinical trial partner, they should clarify how systems are validated, how access and audit trails are managed, and how data will be reported, transferred and archived. Responsibilities for data ownership and access after the contract ends should also be predefined.
7. Are governance and costs sufficiently transparent?
The governance model should define responsibilities, decision-making pathways, reporting expectations and escalation procedures, giving the sponsor clear visibility over progress and emerging risks. Budget proposals should distinguish professional fees, technology, investigator payments and pass-through costs, while stating assumptions, exclusions and change-order conditions.
How should sponsors compare CRO proposals?
The process used to choose a CRO clinical trial partner becomes more consistent when all candidates respond to the same protocol and operational assumptions. As such, a detailed Request for Proposal should define the expected services, countries, timelines, systems and deliverables. Sponsors can then use a weighted decision matrix covering:
| Assessment area | Evidence to request |
|---|---|
|
Relevant experience |
Comparable studies, references and team profiles |
|
Operational capacity |
Resource plan, coverage and subcontracting model |
|
Regulatory capability |
Regulatory submissions and authority interactions |
|
Quality and monitoring |
QMS, audit and risk-based monitoring approach |
|
Recruitment |
Feasibility methodology and site-performance data |
|
Technology |
System documentation and reporting demonstration |
|
Governance and budget |
KPIs, escalation routes and detailed costs |
Bid-defence meetings should involve the professionals expected to lead the study, allowing sponsors to assess their understanding of the protocol, test the assumptions behind recruitment, timelines and costs, and evaluate the credibility of the proposed operating model.
Supporting clinical trials through an integrated CRO model
An integrated CRO model can simplify governance by reducing handovers between regulatory, operational, safety, quality and data functions. This creates a more coherent execution pathway, particularly when decisions in one area have direct implications for timelines, evidence generation or regulatory readiness.
VectorB2B supports clinical programmes from planning and study start-up through execution, close-out and reporting. Our service model can be adapted to the sponsor’s internal capabilities, combining the functions required to maintain continuity across the development programme.
For organisations preparing to choose a CRO partner, VectorB2B can help translate the protocol into a controlled and executable clinical programme, with clear accountability, integrated coordination and continuous visibility over risk, progress and performance.
Explore VectorB2B’s Clinical Services or contact our team to discuss your clinical development programme.
Frequently asked questions (FAQ)
1. What information should a sponsor prepare before approaching a CRO?
Sponsors should prepare a protocol or study synopsis, indication, phase, target population, geographical scope, timeline and required services. Internal responsibilities, recruitment assumptions, technology needs and budget parameters should also be defined.
2. What are the main warning signs when evaluating a CRO?
When sponsors choose a CRO clinical trial partner, warning signs may include vague assumptions, limited access to the proposed study team, unrealistic recruitment forecasts, unclear subcontracting arrangements and insufficient detail on governance, quality systems or change-order conditions.
3. Can a sponsor transfer all clinical trial responsibilities to a CRO?
Sponsors may delegate trial-related activities to a CRO through written agreements, but they must retain adequate oversight. The delegated tasks, decision-making responsibilities, information flows and escalation procedures should be clearly defined from the outset.
